Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-blind, Placebo-controlled Single and Multiple Intravenous Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of GATE-101 in Normal Healthy Volunteers

NCT04618263 is registered in ClinicalTrials.gov with Syndeio Biosciences, Inc as lead sponsor.

NCT NCT04618263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04618263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-blind, Placebo-controlled Single and Multiple Intravenous Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of GATE-101 in Normal Healthy Volunteers
Lead sponsor
Syndeio Biosciences, Inc
Phase
Phase 1
Overall status
Terminated
Start date
October 26, 2020
Completion date
August 13, 2021
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

excessive sleepiness, major depressive disorder